Immunotherapy plus chemo shows promise against rectal cancer
NCT ID NCT06647680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether giving a combination of chemotherapy (oxaliplatin and capecitabine) and the immunotherapy drug tislelizumab before surgery can shrink or eliminate tumors in people with locally advanced rectal cancer. About 35 participants will receive three cycles of the drug combo, then undergo surgery and be followed for up to four years. The goal is to see how many patients have a complete response, meaning no cancer remains detectable after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (PD-1 inhibitor) combined with chemotherapy (oxaliplatin and capecitabine)
- What this could lead to
- If successful, this combination could improve the chance of eliminating the tumor before surgery, potentially reducing the need for more aggressive treatments.
- What could go wrong
- This is a small, early-phase study (35 people) with no control group, so results may not apply broadly. Side effects from chemo and immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The affiliated hospital of Qingdao university
RECRUITINGQingdao, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
- Can a beetroot drink spot dangerous surgical leaks before they turn deadly?